share_log

Jörn Jörgensen Buys Handful Of Shares In EuroEyes International Eye Clinic

ヨルン・ヨルゲンセン氏がEuroEyes International Eye Clinicの株式をいくつか購入しました

Simply Wall St ·  2023/12/07 17:09

Those following along with EuroEyes International Eye Clinic Limited (HKG:1846) will no doubt be intrigued by the recent purchase of shares by Jörn Jörgensen, Founder of the company, who spent a stonking HK$7.8m on stock at an average price of HK$5.19. While that only increased their holding size by 0.8%, it is still a big swing by our standards.

View our latest analysis for EuroEyes International Eye Clinic

The Last 12 Months Of Insider Transactions At EuroEyes International Eye Clinic

Notably, that recent purchase by Jörn Jörgensen is the biggest insider purchase of EuroEyes International Eye Clinic shares that we've seen in the last year. That implies that an insider found the current price of HK$5.30 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. Happily, the EuroEyes International Eye Clinic insiders decided to buy shares at close to current prices.

Over the last year, we can see that insiders have bought 2.77m shares worth HK$15m. But insiders sold 5.00k shares worth HK$29k. Overall, EuroEyes International Eye Clinic insiders were net buyers during the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
SEHK:1846 Insider Trading Volume December 7th 2023

EuroEyes International Eye Clinic is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership Of EuroEyes International Eye Clinic

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. EuroEyes International Eye Clinic insiders own about HK$1.0b worth of shares (which is 57% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At EuroEyes International Eye Clinic Tell Us?

It is good to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about EuroEyes International Eye Clinic. That's what I like to see! If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする